An immunotherapy helps patients live years longer without their cancer getting worse or coming back, a major phase III trial has found. Pembrolizumab kept cancer at bay for some patients for an ...

We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...

Jacqueline joined The Generations Study research team in 2022. Prior to joining the study, she has 14 years of experience working in the NHS in acute hospital, education, and primary care settings, ...

Researchers at The Institute of Cancer Research, London, have uncovered a hidden weakness in some breast cancer tumours that could lead to smarter treatment decisions.

Lucy Dan earned her Master's degree in biological sciences from Durham University. She is a ICR/Imperial Convergence Science Centre student and will investigate novel ways to target the activities of ...

Amy McGeoch earned her Bachelor's degree in biochemistry from the University of Leeds. She plans to investigate the involvement of cyclin-dependent kinase complexes in non-canonical pathways such as ...

A new genetically engineered virus has delivered a one-two punch against advanced cancers in initial findings from a phase I trial. Researchers found that RP2 – a modified version of the herpes ...

The latest major breakthrough in cancer is a drug called capivasertib, which has shown ‘remarkable’ results against advanced breast cancer in its first phase III trial. Results released at the ...

Image of human melanoma tissue, with melanoma cells in green and purple extracellular matrix fibres arranged perpendicular at the border of the tumour. Credit Oscar Maiques Carlos Scientists have ...

A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown. A team from The Institute of Cancer Research, ...

Image: DNA sequence. Credit: The Institute of Cancer Research, London. A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for one ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...